Boric Acid–Nitroimidazole Vaginal Composition for Recurrent BV

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for bacterial vaginosis, particularly recurrent and refractory cases, are ineffective and have high recurrence rates, with limited therapeutic options and significant emotional and economic burdens on patients.

Innovation Solution

A vaginal composition combining boric acid and nitroimidazole, administered simultaneously, to eradicate bacterial biofilms and pathogens, providing a high but safe dose of nitroimidazole in a stable formulation, potentially curing bacterial vaginosis and reducing recurrence rates.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If standard antimicrobial therapy (metronidazole, tinidazole, clindamycin) is used to treat bacterial vaginosis, then short-term symptom relief is achieved, but recurrence rates increase (30-80% within 1 year)

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidduration of cure

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent combines boric acid and nitroimidazole into a single vaginal composition for simultaneous administration. This combination therapy leverages the synergistic effects of both agents against BV pathogens, achieving higher cure rates (70-80%) and longer duration of remission compared to monotherapy, directly addressing the contradiction between short-term effectiveness and long-term durability

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent employs high doses of nitroimidazole (500-1000 mg) in a stable vaginal formulation, representing a parameter change from standard dosing. This high-dose approach, combined with boric acid, achieves more profound microbial eradication and longer-lasting clinical remission, resolving the contradiction between immediate symptom relief and sustained cure

Inventive Principle:

Principle #35Parameter changes

2Ease of operation

If repeated therapy courses are prescribed annually (5-6 courses), then recurrent symptoms are managed, but emotional and economic burden increases

Engineering Contradiction:

Improvesymptom managementVSAvoidnumber of treatment courses

Core Design Contradiction:

Ease of operationVSQuantity of substance

Solution Approach 1:

The patent applies preliminary action by using high-dose nitroimidazole and boric acid combination therapy to achieve complete microbial eradication and long-term remission from the outset. This intensive initial treatment prevents the need for multiple subsequent courses, reducing both the quantity of treatments required and the associated emotional and economic burden while maintaining effective symptom management

Inventive Principle:

Principle #10Preliminary action

3Reliability

If high dose nitroimidazole is administered to improve treatment efficacy, then cure rate increases, but safety concerns arise

Engineering Contradiction:

Improvecure rateVSAvoidtoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses boric acid as an intermediary agent that enhances the efficacy of nitroimidazole while managing its potential toxicity. The combination creates a synergistic effect where boric acid contributes to microbial kill and creates an unfavorable environment for pathogens, allowing high-dose nitroimidazole to be administered safely with improved cure rates and maintained safety profile

Inventive Principle:

Principle #24Intermediary (Mediator)

4Stability of the object's composition

If conventional treatment guidelines are followed for 30 years, then treatment protocols remain stable, but therapeutic advances are insufficient

Engineering Contradiction:

Improveguideline consistencyVSAvoidtherapeutic advancement

Core Design Contradiction:

Stability of the object's compositionVSProductivity

Solution Approach 1:

The patent applies composite materials by formulating a combination of boric acid and nitroimidazole in a stable vaginal composition. This composite approach integrates two mechanisms of action into a single therapeutic product, achieving superior efficacy and durability compared to conventional single-agent therapies, thereby advancing treatment capabilities while maintaining formulation stability

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination therapy effectively eradicates bacterial vaginosis, offering short-term and long-term control with improved patient compliance and reduced recurrence rates, even in refractory cases.

Implementation Method 1

The combination of boric acid and nitroimidazole is synergistic in its activity against vaginal pathogens and biofilms

Methodology Applied

Scientific EffectAntimicrobial action:

Data Source

PatentUS20250268934A1Compositions and Methods for the Treatment of Bacterial Vaginosis

Publication Date: 2025.08.28 EMBIL KORAL

AI summary

Provided herein are methods of treating vaginitis by simultaneous local application per vagina of both boric acid and nitroimidazole. Also provided are compositions useful in such treatments, for instance containing 100-1,000 mg of nitroimidazole and 300-900 mg boric acid. Vaginal application of nitroimidazole allows a higher but safe dose to be administered simultaneously with boric acid for the effective treatment of bacterial vaginosis (BV). Also provided are methods for prophylactic treatment of patients, such as those prone to recurrent BV.